Inclusion Criteria:

- diagnosis of advanced non-small cell lung cancer (NSCLC) not amenable to curative
treatment. Patients enrolling in Part 2 of the study must have the above stated
diagnosis of NSCLC that is also of nonsquamous histology.

- no prior systemic therapies (chemotherapy, etc.)or pleurodesis with chemotherapy for
this disease

- prior radiotherapy is allowed but must be completed at least 2 weeks before study
enrollment and patient must be recovered from the acute toxic effects

- have a good performance status

- patient must sign an informed consent document

Exclusion Criteria:

- patient had myocardial infarction occurring less than 6 months before inclusion,
uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not
controlled by medications

- patient is unable to swallow tablets

- patient is taking a certain medicine to control seizure activity, called "enzyme
inducing antiepileptic drugs" and is not able to stop taking the medicine prior to
enrolling in the study

- patient is unable to interrupt aspirin and/or other anti-inflammatory agents

- patient is unwilling or unable to take vitamin supplementation (folic acid and
vitamin B12) or medications to prevent side effects